2025年6月23日星期一 ➢ 美军突袭伊朗核设施；联储理事料最 快7月降息。A股持续收低。上证指数 收盘跌0.07%报3359.9点，深证成指跌 0.47%，创业板指跌0.83%。脑机接口 概念回落。港股下跌。恒生指数收盘 涨1.26%报23530.48点，恒生科技指数 涨0.88%，恒生中国企业指数涨1.38%。 大金融强势，油气股放缓。大盘成交 额2224.23亿港元。外盘方面，欧洲三 大股指收盘涨跌不一。美国三大股指 收盘涨跌不一，道指涨0.08%，标普 500指数跌0.22%报5967.84点，纳指跌 0.51%。美军周末突袭伊朗三处核设施， 德黑兰誓言保留一切反击选项。特朗 普再次威胁解雇鲍威尔，美联储理事 Waller预计最快可在7月降息。 资料来源：彭博 | 23530.48 | 1.26 | 17.30 | | --- | --- | --- | | 8527.07 | 1.38 | 16.97 | | 5133.14 | 0.88 | 14.88 | | 130.57 | -0.74 | -8.69 | | 3359.90 | -0.07 | 0.24 | | 10005.03 | -0. ...

与此同时，安进的实验性减肥疗法MariTide的安全性将成为关注焦点。该公司将于6月23日公布一项关 于这种注射剂的二期临床试验的全部数据。 安进的股票在11月份出现了下跌，原因是该公司报告称，MariTide在为期52周的试验中使受试者的平均 体重减轻了多达20%。该试验招募的对象为患有肥胖症或超重症但未患有2型糖尿病的个体。 减肥药巨头礼来(LLY.US)、诺和诺德(NVO.US)以及安进(AMGN.US)计划在6月20日至23日于芝加哥举 行的美国糖尿病协会(ADA)第85届科学会议上公布其重大临床试验的结果。 礼来将于6月21日在由ADA主办的研讨会上公布其针对2型糖尿病成年患者的在研口服减肥疗法 (orforglipron)的3期临床试验结果。这家制药公司于4月公布了ACHIEVE-1试验的最终数据，指出这项全 球性试验(orforglipron的七项3期临床试验中的第一项)达到了主要目标，即这种每日服用一次的药物在 40周的试验期内使患者平均减重约8%。 诺和诺德也将于6月22日参加研讨会，公布其下一代减肥疗法CagriSema的REDEFINE1和REDEFINE2三 期临床试验的数据。这家丹麦 ...

高盛认为在"下一代减肥药物" MariTide相关的重大催化之下，安进有望踏上价值重估轨迹，其股价上行 空间相比于同行可能更加广阔。高盛表示，安进当前仅仅14x的2025年预期PE显著低于其所处的生物科 技板块均值(22x)，目标价400美元对应该公司股价大约40%上行空间。 智通财经APP获悉，美国生物科技巨头安进公司(AMGN.US)将在2025年6月23日举行的美国糖尿病学会 (ADA) 年会上公布"下一代减肥药物" MariTide 在肥胖症适应症中的II 期(第一部分)完整临床数据。该试 验针对肥胖或超重且无Ⅱ型糖尿病的患者开展，为期52周，管理层虽然表示，2024年11月公布的顶线数 据已经涵盖了大部分关键数据，但高盛预计本次完整数据披露仍将成为安进乃至整个减肥药领域公司的 重要股价上行催化剂，安进将能够提供此前摘要数据中未涵盖的细节和洞见。 高盛在最新发布的研报中表示，一项关于MariTide的I期药代动力学剂量递增研究结果也将同期发布， 这些新增数据有望进一步澄清 MariTide 的临床特性。高盛预计MariTide实现"双面突破"的可能性非常大 ——即减肥药物的巨大潜力与临床争议的平衡均取 ...

MariTide is the First Monthly or Less Frequently Dosed Peptide-Antibody Conjugate Being Investigated for the Treatment of Obesity and Type 2 Diabetes THOUSAND OAKS, Calif., June 18, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced full results from Part 1 of the Phase 2 study for MariTide (maridebart cafraglutide, formerly AMG 133) in patients living with obesity, with and without Type 2 diabetes, will be presented along with new data from the Phase 3 FOURIER study of Repatha® (evolocumab) in cardio ...

Group 1 - Amgen's stock price remains above its volume-weighted average price (VWAP) despite the ongoing conflict between Israel and Iran, with a notable increase of approximately 15% over the past month [1] Group 2 - Allka Research has over two decades of experience in investment, focusing on identifying undervalued assets in various sectors including ETFs, commodities, technology, and pharmaceuticals [2] - The firm emphasizes a conservative investment approach, aiming to deliver substantial returns and strategic insights to clients [2] - Allka Research is committed to simplifying investment strategies to make them accessible for both seasoned and novice investors [2] - The organization seeks to empower individuals financially by sharing knowledge and analyses through platforms like Seeking Alpha [2] - Allka Research aims to foster a community of informed investors who can navigate the complexities of the financial markets with confidence [2]

Amgen Inc. (NASDAQ:AMGN) Goldman Sachs 46th Annual Global Healthcare Conference Call June 10, 2025 9:20 PM ET Company Participants James E. Bradner - Executive Vice President of Research & Development Justin G. Claeys - Vice President of Investor Relations Peter H. Griffith - Executive VP & CFO Conference Call Participants Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division Salveen Jaswal Richter Great. Good morning, everyone. Thank you so much for joining us. I'm really pleased to have wi ...

Financial Data and Key Metrics Changes - First quarter revenues grew by 9% year over year, with non-GAAP EPS increasing by 24% [5] - The revenue from Repatha reached $656 million, up 27% year over year [5] - The rare disease portfolio generated over $1 billion in product sales in the first quarter [7] - The biosimilars portfolio generated $735 million in product sales, up 35% year over year [9][10] - Operating margin is guided to be around 46% for the year, down from 47% last year due to increased R&D opportunities [32] Business Line Data and Key Metrics Changes - General medicine products, including Repatha and Evenity, showed strong growth, with Repatha being a multibillion-dollar product [5][16] - TESPIRE in inflammation grew by 65% year over year [7][19] - The oncology segment, particularly the T cell engager platform, saw a 52% growth in BLINCYTO [8][16] - The rare disease segment continues to show strength with products like Euplisna and KRYSTEXXA [18] Market Data and Key Metrics Changes - Cardiovascular disease remains a leading cause of mortality, driving growth for Repatha [5] - The market for obesity treatments is vast, with estimates suggesting over a billion people affected globally [46] - The company is optimistic about expanding its presence in the rare disease market, particularly with new launches [18][60] Company Strategy and Development Direction - The company's strategy focuses on execution in both the end market portfolio and the advancing pipeline [16][23] - Significant capital allocation is planned for expanding manufacturing capabilities, with $2.3 billion in CapEx for the year [21] - The company is actively engaging in business development opportunities, including collaborations and acquisitions [26][28] Management's Comments on Operating Environment and Future Outlook - Management is closely monitoring the policy and macro environment, including tariffs and drug pricing [10][32] - The company is optimistic about its innovation pipeline and believes it can navigate the current challenges effectively [30][33] - There is a strong focus on patient access and value, with ongoing engagement with policymakers [28][30] Other Important Information - The company is preparing for a PDUFA date for Euplisna in generalized myasthenia gravis [7][60] - Upcoming data presentations at the American Diabetes Association meeting will provide insights into the Meritide program [13][34] Q&A Session Summary Question: What are the key priorities for the company today and what is the forward strategy? - The key strategy is focused on execution in the end market portfolio and rapidly advancing pipeline [16] Question: How important is business development as a lever for the company? - The company maintains an open approach to business development, looking at all opportunities for innovation [26] Question: How is the company engaging with policymakers regarding drug pricing? - The company is actively engaged with policymakers to advocate for innovation and patient access [28] Question: What is the outlook for the obesity market and how will Meritide be positioned? - The obesity market is large and underpenetrated, with Meritide expected to compete effectively across various settings [46][48] Question: What are the commercial opportunities for the recently launched drugs? - The company sees significant potential in IgG4 mediated diseases and myasthenia gravis, with strong efficacy profiles [60][61]

Group 1 - The article discusses the analytical approach of a healthcare and tech stock analyst who combines clinical insights with valuation methods to identify investment opportunities [1] - The analyst specializes in scenario-based DCF modeling, sensitivity analysis, and Monte Carlo simulations to assess asymmetric risk-reward profiles [1] - The focus is on translating complex scientific and market dynamics into actionable investment theses, influenced by concepts from "Superforecasting" and "Fooled by Randomness" [1] Group 2 - The article emphasizes the importance of independent verification of information and conducting thorough research before making investment decisions [3] - It highlights that past performance is not indicative of future results and that no specific investment recommendations are provided [4]

THOUSAND OAKS, Calif., June 5, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the Goldman Sachs 46th Annual Global Healthcare Conference at 9:20 a.m. PT on Tuesday, June 10, 2025. Peter Griffith, executive vice president and chief financial officer at Amgen, and Jay Bradner, executive vice president of Research and Development at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and t ...

Amgen (AMGN) 2025 Conference Summary Company Overview - **Company**: Amgen (AMGN) - **Event**: Jefferies Healthcare Conference, June 04, 2025 Key Points Financial Performance - First quarter revenues increased by **9%**, with non-GAAP earnings per share up **24%** year over year [6] - **14 products** delivered double-digit growth, indicating broad-based strength in the portfolio [6] Product Highlights - **Repatha** and **Evenity** generated over **$1 billion** in revenue in Q1, up **28%** year over year [7] - Significant market opportunity exists with **100 million** patients needing LDL cholesterol lowering and **90%** of very high-risk patients for postmenopausal osteoporosis not receiving appropriate therapy [7] - **Opasiran** is fully enrolled in its phase three cardiovascular outcomes trial [10] - **Euplisna** launched as the first FDA-approved therapy for IgG4-related disease, with a PDUFA date set for December 14 [10] - **TESPIRE** continues to grow in severe uncontrolled asthma, with a PDUFA date for chronic rhinosinusitis with nasal polyps on October 19 [11] - **Biosimilars** generated **$735 million** in revenue in Q1, up **35%** year over year [14] Pipeline and R&D - The company is focused on advancing its pipeline across various therapeutic areas, including general medicine, rare diseases, inflammation, and oncology [5][10] - Upcoming data presentations at the ADA meeting will include results from the **Meritide** phase II trial [7][49] Market Dynamics - The company is aware of the competitive landscape, particularly regarding the launch of biosimilars for **denosumab** [17][26] - Despite concerns about biosimilars, Amgen expects to maintain growth through strong performance of existing products [17][46] Strategic Focus - Amgen emphasizes the importance of innovation and is actively engaging with policymakers to improve patient access while supporting sustainable R&D [15][16] - The company is committed to maintaining a disciplined capital allocation strategy, focusing on innovation, business investment, and returning capital to shareholders [44] Competitive Positioning - Amgen believes its diverse portfolio of growth drivers mitigates risks associated with biosimilars [21] - The company is confident in the competitive differentiation of its products, particularly **Meritide**, which is positioned as a unique offering in the weight management market [49][50] Future Outlook - The company anticipates continued strong growth in branded products, with manageable impacts from biosimilars [46] - Amgen is preparing for significant data releases and product launches in the coming months, which are expected to bolster its market position [88][92] Additional Insights - The company is leveraging technology and AI to enhance operational efficiency and R&D processes [45] - Amgen's focus on patient-friendly delivery systems for its products is expected to improve patient adherence and experience [63][80] This summary encapsulates the key insights and strategic directions discussed during the Amgen conference, highlighting the company's robust financial performance, innovative pipeline, and competitive positioning in the biotechnology sector.